04.18.22
Delpharm is investing € 28 million on a sterile line to manufacture prefilled syringes at its plant in Tours, France.
Delpharm began the project in April 2021 to create a new building dedicated to these dosage forms and will start manufacturing in 1Q23. With state-of-the-art equipment including isolator technology, Delpharm Tours will be able to produce between 25 and 30 million syringes per year.
The company will offer a wide range of formats and syringes and the manufacturing plant will provide glass, plastic, subcutaneous, intra-nasal and oro-mucosal prefilled syringes with formats from 1 ml to 50 ml.
Headquartered in France, Delpharm is a CDMO that serves 120 countries.
Stéphane Lepeu, Delpharm's Chief Commercial Officer, said, "Delpharm is convinced that this additional capacity in prefilled syringes is a key investment to answer the growing need on this strategic dosage form.”
This investment will enable Delpharm to recruit an additional 20 to 40 people at its Tours site.
Visit Delpharm at CPhI NA booth 705
Delpharm began the project in April 2021 to create a new building dedicated to these dosage forms and will start manufacturing in 1Q23. With state-of-the-art equipment including isolator technology, Delpharm Tours will be able to produce between 25 and 30 million syringes per year.
The company will offer a wide range of formats and syringes and the manufacturing plant will provide glass, plastic, subcutaneous, intra-nasal and oro-mucosal prefilled syringes with formats from 1 ml to 50 ml.
Headquartered in France, Delpharm is a CDMO that serves 120 countries.
Stéphane Lepeu, Delpharm's Chief Commercial Officer, said, "Delpharm is convinced that this additional capacity in prefilled syringes is a key investment to answer the growing need on this strategic dosage form.”
This investment will enable Delpharm to recruit an additional 20 to 40 people at its Tours site.
Visit Delpharm at CPhI NA booth 705
